Mecanismos de pago en salud: resultados de ejecución del pago asociado a diagnóstico en cirugía bariátrica en su primer año de implementación en Chile / Healthcare payment mechanism: Execution results of bundled payment program for bariatric surgery diagnosis in its first year of implementation in Chile

Introducción Más de 600 mil personas en Chile viven con obesidad mórbida. La incorporación de intervenciones terapéuticas eficaces, seguras y costo-efectivas es crítica para los sistemas de salud y esquemas de aseguramiento. En el año 2022 se incorporaron al arancel de modalidad de libre elección del Fondo Nacional de Salud dos códigos de pago asociado a diagnóstico para cirugía bariátrica: gástrico y manga gástrica. El objetivo fue caracterizar la ejecución del programa de mecanismo de pago tipo pago asociado a diagnóstico de cirugía bariátrica en su primer año de implementación. Métodos Estudio descriptivo y observacional de abordaje pragmático de la ejecución nacional del pago asociado a diagnóstico en cirugía bariátrica. Se examinaron variables de caracterización sociodemográfica (sexo, tramos etarios y tramos del Fondo nacional de Salud) y caracterización de cirugías según código desagregadas por prestador público o privado, periodo de emisión, gasto unitario, copago, y préstamos médicos, entre marzo y diciembre de 2022. Resultados Se registraron n = 13 118 cirugías (45,81% versus 54,19% manga), de las cuales n = 2424 (18,48%) emplearon préstamos médicos. Un 85,01% (p = 0,01) de los procedimientos fueron en mujeres; en personas entre 35 y 39 años (20,15%); y 45,12% en beneficiarios del tramo B. El 99,21% de las cirugías se realizó en prestadores privados. Diez de estos concentraron el 50% de la actividad (rango n = 1200 a 426 cirugías anuales; n = 4,8 a 1,7 cirugías por día hábil). El gasto total del programa fue $71 626 948 350 CLP, explicando un 5,04% de la actividad total del Programa nacional de Pago Asociado a Diagnóstico. Conclusiones La implementación de este bono para cirugía bariátrica benefició a más de 13 mil personas que viven con obesidad, mayormente mujeres, en edades productivas, y con capacidad de compra. Como estrategia de equidad, independientemente de la vía de acceso mediante el bono, será importante cautelar la actividad en la red pública.

Introduction More than 600 thousand people in Chile live with morbid obesity. Effective, safe, cost-effective therapeutic interventions are critical for healthcare systems and insurance schemes. In 2022, two bundled payment codes for bariatric surgery (gastric bypass and gastric sleeve) were incorporated into the National Health Fund's free-choice modality fee scheme. The objective was to characterize the execution of this payment mechanism program associated with bariatric surgery diagnosis in its first year of implementation.More than six hundred thousand people in Chile are estimated to live with morbid obesity. Effective, safe, cost-effective therapeutic interventions are critical for health systems and insurance schemes. In 2022, FONASA incorporated two Bariatric Surgery codes into the Free Choice Modality: Gastric Bypass and Sleeve Gastrectomy. Our objective was to characterize the execution of the Bariatric Surgery Bundled Payment Program in its first year of implementation. Methods Descriptive and observational study of the pragmatic approach of the national execution of the payment associated with diagnosis in bariatric surgery. We examined sociodemographic variables (sex, age brackets, and National Health Fund tranches) and characterization of surgeries by code broken down by public or private provider, period of issue, unit cost, co-payment, and medical loans between March and December 2022. Results We recorded n = 13 118 surgeries (45.81% bypass versus 54.19% sleeve), of which n = 2424 (18.48%) used medical loans. A total of 85.01% (p = 0.01) of the procedures were in women, in people between 35 and 39 years of age (20.15%), and 45.12% in beneficiaries of tranche B. Private providers performed a total of 99.21% of the surgeries. Ten accounted for 50% of the activity (range n = 1200 to 426 surgeries per year; n = 4.8 to 1.7 surgeries per working day). Total program expenditure was $71 626 948 350 CLP, accounting for 5.04% of the total activity of the national Diagnosis Associated Payment Program. Conclusions The implementation of this bariatric surgery voucher benefited more than 13 thousand people living with obesity, mostly women of productive ages and with purchasing capacity. As an equity strategy, regardless of the access route through the voucher, it will be important to safeguard the activity in the public network.

Semimonthly Table of Contents Application of health technology assessment in 4 European countries and its enlightenment to China / 中国药房

OBJECTIVE To provide referen ce for improving the application of health technology assessment （HTA） in decision-making for health insurance drugs in China. METHODS The application of HTA in decision-making for health insurance drugs in Britain ，France，Germany and Sweden were sorted out and analyzed from two aspects ：the establishment of HTA institutions and the process of HTA. The suggestions for improvement were put forward ，combined with the implementation of HTA in China. RESULTS & CONCLUSIONS Britain，France，Germany and Sweden have set up special HTA institutions ，which perform their respective duties and cooperate closely. During the implementation of HTA ，the above four countries have set different value assessment criteria to screen drugs with “high cost performance ”，all stakeholders actively participate ，make the evaluation results and decisions public ，set up objection handling links ，open a rapid evaluation channel to improve the accessibility of drugs ，and re-evaluate the drugs included in the reimbursement list to ensure the sustainability of medical insurance. It is suggested that China should combine the national conditions ，strengthen the cooperation of HTA institutions ，focus on talent training and comprehensive value assessment criteria ， promote stakeholder ’s participation ， improve the transparency of decision-making，and improve the implementation procedures of HTA in China.

Social support status and influencing factors among schizophrenics in remission in Northeast Sichuan / 四川精神卫生

ObjectiveTo investigate the social support status and influencing factors of schizophrenics in remission in Northeast Sichuan， and to provide ideas for improving their social support. MethodsFrom May to September 2020， a total of 533 patients who met the diagnosis criteria of the International Classification of Diseases， tenth edition （ICD-10） for schizophrenics in remission at the mental health institutions in Guangyuan， Bazhong and Dazhou cities were selected for the survey， and patients were assessed by self-made demographic and clinical data inventory and Social Support Rating Scale （SSRS）. Then the social support status of schizophrenic in remission and influencing factors were analyzed， meantime， the impact of the second round reimbursement policy of medical insurance benefits on their social support was addressed particularly. Results①The SSRS total score， objective support， subjective support， and utilization of support scores of schizophrenics in remission were lower than those of the national norm （t=5.065~30.382， P<0.01）. ②Univariate analysis showed that SSRS score was relatively high among patients with female gender （t=-3.632）， retired status （F=5.951）， married status （F=5.951）， spouse as primary caregiver （F=23.841）， annual household income >5 000 yuan （F=15.892）， patient's economic income （t=4.083）， and outpatient or online follow-up （F=3.954）， with statistically significant differences （P<0.05 or 0.01）. ③The total and dimensional scores of SSRS in patients with access to the second round medical insurance reimbursement were significantly higher than those without （t=10.195~25.103， P<0.01）. ④Multiple linear regression analysis denoted that gender， work status， marital status， primary caregivers， annual family income， economic income， follow-up visits and the second round medical insurance reimbursement were the factors influencing social support status of schizophrenics in remission （β=0.201~2.115， P<0.05 or 0.01）. ConclusionThe social support of schizophrenics in remission in Northeast Sichuan is below the national average， furthermore， their social support levels are affected by the gender， work status， marital status， primary caregivers， annual family income， economic income， follow-up visits and the second round medical insurance reimbursement， and the second round medical insurance reimbursement may ameliorate the social support status of patients.

Attention Situation of Chinese Patent Medicine for Constipation in Traditional Chinese Medicine Diagnosis and Treatment Guidelines/Consensus and National Reimbursement Drug List / 中国实验方剂学杂志

ObjectiveTo evaluate the methodological quality of traditional Chinese medicine （TCM） diagnosis and treatment guidelines/consensus of constipation with Appraisal of Guidelines for Research and Evaluation Ⅱ （AGREE Ⅱ）tool， and to study the attention situation of the included Chinese patent medicines in China's National Reimbursement Drug List in the guidelines/consensus. MethodThe data of CNKI，VIP，Wanfang Data，SinoMed，PubMed and Cochrane from the inception of the databases to October 2021 were searched to collect the TCM diagnosis and treatment guidelines/consensus of constipation. Then，the diagnosis and treatment standards and recommended Chinese patent medicines were extracted. Two researchers assessed the methodological quality of the guidelines/consensus with AGREE Ⅱ tool independently. The quality of reports was evaluated by Reporting Items for practice Guidelines in HealThcare （RIGHT） Statement. The recommended Chinese patent medicines in the guidelines/consensus were compared with those in the National Reimbursement Drug List. ResultEleven consensus and 2 guidelines were included，involving 794 experts. The scores of AGREE II were clarity of presentation（59.0%），scope and purpose（44.0%），stakeholder involvement（23.1%），rigor of development （12.1%），applicability （11.1%），and editorial independence （8.3%） from high to low. Five articles were recommended at B level（recommended after revision） and 8 articles were at C level （not recommended）. The average scores of RIGHT Statement were as follows：basic information （93.59%），background （57.69%），evidence （18.46%），recommendations （20.88%），review and quality assurance （19.23%），funding，declaration and management of interests （0.00%）， and other information （0.00%）. The included guidelines/consensus recommended a total of 27 Chinese patent medicines，among which 20 were included in the National Reimbursement Drug List，with 4 species of Class A and 16 species of Class B， accounting for 74.1% of all recommended Chinese patent medicines. Ten purgative Chinese patent medicines in the National Reimbursement Drug List were recommended by the guidelines/consensus，accounting for 50% of all purgative drugs， and 8 were not recommended. There were prescriptions for purgation， for promoting digestion and removing food stagnation， for clearing heat and purging fire，and for warming the middle and dissipating cold，Tibetan medicine and Mongolian medicine. ConclusionBy the AGREE Ⅱ assessment，the methodological quality of the TCM diagnosis and treatment guidelines/consensus of constipation included in this study needed to be improved in the future. The report quality evaluated with RIGHT Statement was low. Most drugs included in the National Reimbursement Drug List were paid attention in the TCM diagnosis and treatment guidelines/consensus of constipation. Moreover，the drugs included in the National Reimbursement Drug List could basically fulfill the clinical needs reflexed from the guidelines/consensus recommendations. However， the reasons of some drugs failing to be included in the National Reimbursement Drug List needed to be studied in the future.

Pagamentos por desempenho na atenção primária à saúde: uma revisão sistemática / Pay-for-performance in primary health care: a systematic review

Revisão sistemática acerca da efetividade da remuneração por desempenho na melhoria de indicadores de processo/resultado em programas e serviços de atenção primária à saúde. Realizou-se busca na PubMed, Scopus, Web of Science, SciELO e Biblioteca Virtual de Saúde, resultando em 22 estudos analisados quanto ao tipo de estudo, objetivo, qualidade da evidência e principais achados. Constatou-se que a remuneração por desempenho apresentou impacto na atenção clínica às doenças, acessibilidade aos serviços, melhoria nos processos de acompanhamento e rentabilidade da utilização e apresenta-se como estratégia potencial à indução de melhorias na qualidade nos serviços de saúde, ainda que consideradas suas limitações.

A systematic review of the effectiveness of pay for performance in the improvement process of indicators/results in primary health care programs and services. A search was conducted in PubMed, Scopus, Web of Science, SciELO, and Virtual Health Library, resulting in 22 studies analyzed as to the type of study, objective, evidence quality, and main findings. It was found that the pay for performance impacted clinical care to disease, accessibility to services, improving the monitoring of processes, and profitability of use and presents itself as a potential strategy to induce improvements in the quality of health services, although considering its limitations.

Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS): an urgent need for treatment management

ABSTRACT Introduction: Chronic Myeloid Leukemia (CML) is a myeloproliferative disease that affects mainly adults between 50 and 55 years. In Brazil, information from the Sistema Único de Saúde (SUS) Outpatient Information System indicates that 12,531 patients had the Autorização de Procedimento Ambulatorial (APAC) approved for the CML treatment in 2017. Disease monitoring through molecular response evaluation is critical to the care of CML patients. The quantitative PCR test (real-time polymerase chain reaction) provides adequate evaluation parameters that allow the health professional to intervene at the right moments in order to reduce the chance of progression of the disease, providing the best outcome to the patient, including the possibility of treatment discontinuation for eligible patients. Although the test is included in the Clinical Protocol and Therapeutic Guidelines (PCDT) of CML, it is not possible to monitor the molecular response within SUS since there is no reimbursement for this test. Objective: Obtain expert recommendations on the importance, financing, and reimbursement of molecular monitoring in SUS. Methods: Six CML experts with different perspectives participated in the panel. The discussion was based in the main publications about the quantitative PCR test in CML monitoring. Results: Experts' recommendations: Molecular monitoring should be part of the integral treatment of patients with CML to reduce the chances of disease progression and costs to the health system; The government should put into practice what is provided in the PCDT of Chronic Myeloid Leukemia in Brazil: performing the monitoring of the molecular response via quantitative PCR; The government should create a code with adequate nomenclature and reimbursement value in SIGTAP, so that the test is carried out and covered by the public health network, as it is contained in the PCDT of the disease and the existing APAC does not cover the operational costs for its performance; Patients with chronic phase CML should perform a quantitative PCR every 3 months and, after reaching the MMR, should perform the examination every 6 months, as recommended by international guidelines; Patients should be monitored in reference laboratories that are standardized according to the international scale; The laboratories that are within the reference public centers could absorb all the test demand in Brazil, and other centers could be qualified through an ABHH accreditation; Adequate molecular monitoring may allow some patients to stop taking drugs and selffinancing the molecular test for all SUS patients Conclusion: A solution for the molecular test (BCR-ABL1) funding is urgent to ensure the monitoring of CML patients in SUS. The savings that might be generated with patients that stop taking the medication when adequately monitored may finance the test.

Lista de pacientes: reflexões para a prática da medicina de família e comunidade / List of patients: reflections for the practice of family and community medicine / Lista de pacientes: reflexiones para la práctica de la medicina familiar y comunitaria

Este artículo analiza el tema de la lista de pacientes como modelo para vincular a la población con los equipos de Atención Primaria de Salud (APS). Objetivo: destacar las características de la lista de pacientes como modelo de pago. Método: ensayo teórico sobre modelos de pago que analiza el piloto de lista de pacientes de la Secretaría Municipal de- Salud (SMS) de Florianópolis. Para fundamentar los principios de la lista de pacientes, su aplicación se presenta en dos contextos diferentes: (a) en el sistema de salud cerrado, como en las Organizaciones de Mantenimiento de la Salud (HMO) en los Estados Unidos; y (b) en el sistema de salud universal, utilizando el sistema de salud británico como modelo. Discusión: el proyecto piloto de lista de pacientes de la SMS de Florianópolis enfrenta dos problemas estructurales: (a) el sistema de salud universal que caracteriza a la APS brasileña; y (b) el modelo de pago de salarios. Estos dos componentes plantean el desafío de establecer un límite real para las listas de pacientes. Sin límite en el número de pacientes, no es posible ajustar la carga de trabajo de los profesionales de la salud. Adicionalmente, una lista de pacientes basada en el uso repetido y el atendimiento de casos de agudeza fuera de la lista tiende a incrementar la carga de trabajo de los profesionales con el tiempo. No obstante, la lista de pacientes propuesta proporciona una mayor visibilidad de la carga de trabajo facilitando tanto la gestión como el seguimiento de la presión asistencial y la redistribución interna de los pacientes entre los equipos de salud de la APS. También permite justificar la ampliación de los equipos de la Estrategia Salud de Familia (ESF) según datos más fiables sobre la realidad de los servicios e implementar programas de mejora de la calidad. Conclusión: la implementación de la modalidad de vinculación flexible en Florianópolis no tiene impactos positivos directos en la carga de trabajo de los equipos de salud, pero quizás sí de manera indirecta a través de la gestión inteligente de su sistema de APS.

This article discusses the theme of patient list as a model for registering the population to the Primary Health Care (PHC) teams. Objective: to highlight the characteristics of patient list as a payment model. Method: theoretical essay on payment models that analyses the pilot of patient list of the Municipal Health Secretariat (MHS) of Florianopolis. To support the principles of the patient list, its application is presented in two different contexts: (a) in closed health systems, as in the Health Maintenance Organizations (HMO) in the United States; and (b) in universal health systems, using the British health system as a model. Discussion: the Florianopolis MHS patient list pilot-project faces two structural problems: (a) the universal health system that characterises Brazilian PHC; and (b) the salary payment model. These two components pose the challenge of establishing a real cap for patient lists. Without a limit on the number of patients, it is not possible to adjust health professionals' workload. Additionally, a list of patients based on repeated use and on the care of out-of-list acute cases tend to increase the workload of professionals over time. Nonetheless, the proposed list of patients provides greater visibility of the workload facilitating both management and monitoring of care pressure and the internal redistribution of patients among the PHC health teams. It also makes it possible to justify the expansion of Family Health Strategy (FHS) teams according to more reliable data on the reality of services and to implement quality improvement programmes. Conclusion: the implementation of the flexible registering modality in Florianopolis does not have direct positive impacts on the workload of health teams, but perhaps it does indirectly through intelligent management of its PHC system.

Este artigo discute o tema da lista de pacientes como modelo de vinculação da população às equipes de Atenção Primária à Saúde (APS). Objetivo: evidenciar as características da lista de pacientes enquanto modelo de pagamento. Método: ensaio teórico sobre modelos de pagamento que analisa o piloto de lista de pacientes da Secretaria Municipal de Saúde (SMS) de Florianópolis-SC. Para fundamentar os princípios da lista de pacientes apresenta-se sua aplicação em dois contextos diferentes: (a) em sistemas fechados de saúde, como nas Health Maintenance Organizations (HMO) nos Estados Unidos; e (b) em sistemas universais de saúde, utilizando o sistema de saúde britânico como modelo. Discussão: o projeto piloto de lista de pacientes da SMS/Florianópolis enfrenta dois problemas estruturais: (a) o sistema de saúde universal que caracteriza a APS brasileira; e (b) o modelo de pagamento salarial. Esses dois componentes impõem o desafio de se estabelecer um teto real para as listas de pacientes. Sem um limite no número de pacientes não é possível adequar a carga de trabalho dos profissionais de saúde. Adicionalmente, uma lista de pacientes construída com base na utilização repetida e no atendimento de casos agudos não fidelizados tende a aumentar a carga de trabalho dos profissionais com o passar do tempo. Entretanto, a proposta da lista de pacientes confere maior visibilidade da carga de trabalho para a gestão, facilitando o monitoramento da pressão assistencial e a redistribuição interna dos usuários entre as equipes de saúde da APS. Permite também justificar a expansão das equipes de ESF de acordo com dados mais fidedignos da realidade dos serviços e implementar programas de melhoria de qualidade. Conclusão: a implantação da modalidade de vinculação flexível em Florianópolis não traz impactos positivos diretos na carga de trabalho das equipes, mas talvez de forma indireta por meio de uma gestão inteligente da rede da APS.

Analysis on the filing mechanism for cross provincial immediate reimbursement of medical insurance in China / 中华医院管理杂志

Objective:To analyze the filing mechanism for cross provincial immediate reimbursement of medical insurance in China, so as to provide reference for optimizing the filing mechanism and improving the filing accessibility of insured personnel.Methods:Taking the filing policy of cross provincial immediate reimbursement of medical insurance in 2019 as the research object, on the basis of a comprehensive understanding of the national filing policy background, 90 coordinating regions in Zhejiang Province, Hubei Province and Ningxia Hui Autonomous Region were taken as survey samples to evaluate the relevant policies and extract key parameters, including filing identification methods, filing-related settlement benefits and filing ways. The parameters were compared and analyzed by using descriptive statistical methods.Results:The results of the survey showed that in terms of identity recognition methods, the provision of various supporting materials(residence permit, work certificate, etc.)was still the main way to carry out identity recognition for medical insured persons in different places.Filing-related reimbursement benefits were mainly adjusted by limiting the area of medical insurance treatment and adjusting the benefits parameters(reimbursement ratio). In terms of filing channels, 51(56.7%)sample co-ordination areas had realized at least one remote filing mode.Conclusions:The inclusiveness of filing identity verification mechanism for the floating population needs to be further improved, the filing-related treatment policies need to be further improved, and the convenience and standardization of filing channels need to be strengthened.

International innovative health technology payment strategy and enlightenment under diagnosis-related groups payment system / 中华医院管理杂志

Under the diagnosis-related groups(DRG) prospective payment system, innovative health technologies with high costs and risks may be limited to some extent. How to balance the increase of health care cost and the development of innovative health technology is a difficult problem to be solved in the current reform. By studying the relatively mature payment systems of innovative health technologies in the world, the authors found that countries generally adopted additional payment or compensation to encourage the development of new technologies. But at the same time, a relatively perfect health technology assessment and payment management mechanism had been established to ensure the standardized operation of payment plan. These international advanced experience and practice could provide references for China′s innovative health technology payment strategy under the DRG payment system. It is suggested to establish a scientific and reasonable assessment mechanism of innovative health technology, create a special access channel for innovative health technology with limited short-term evidence, and gradually form a long-term incentive mechanism of innovative health technology in DRG payment system.

Investigation on Synergistic Effect between Centralized Drug Quantity Purchase Policy and Medical Insurance Reimbursement System / 中国药房

OBJECTIVE：To investigate the synergistic effect and deficiencies between centralized drug quantity purchase policy and medical insurance reimbursement system ，and to provide feasible suggestion to further improve its synergistic effect. METHODS：The literature analysis method and policy evaluation method were adopted to expounds the direct and indirect synergistic effect between the current centralized drug quantity purchase policy and medical insurance reimbursement system in China，and analyze the existing problems so as to put forward the feasible suggestions. RESULTS & CONCLUSIONS ：The centralized drug quantity purchase policy had a direct impact on the payment mode of medical insurance reimbursement system in technical level ，performance evaluation in effect level and process control in management level. The indirect synergy included ： centralized drug quantity purchase policy could promote the adjustment of drug supply security system to adapt to the reform of medical insurance payment ；it could adjust the pharmaceutical market ，and affect the reform of medical insurance reimbursement system. The disadvantages were as follows ：the varieties of selected drugs was still narrow ，and there was room for further improvement in purchasing scope and medical insurance fee reduction ；“one-size-fits-all”payment standard for unselected drug might weaken pharmaceutical companies ’enthusiasm for generic drug research and development. Therefore ，the next step is to significantly expand the variety and scope of procurement ，and appropriately liberalize the medical insurance payment restrictions for drugs with fewer varieties ；coordinate medical insurance reimbursement policies and procurement programs ，and improve the rationality and perfection of medical insurance payment ；guide the medical institutions to change the concept from “price-based medical treatment ”to“value-based medical treatment ”，take into account the interests of all parties in the market ，so as to form a comprehensive coordination adjustment mechanism of drug price and medical insurance reimbursement system.

International Experience and Enlightenment of Medical Insurance Reimbursement for Multi-indication Drugs Based on Value-based Pricing / 中国药房

OBJECTIVE：To provide reference for improving medical insurance reimbursement for multi-indication drugs based on value-based pricing in China. METHODS：The theory and practice of value-based pricing for multi-indication drugs were sorted out，and the value standards and medical insurance reimbursement strategies based on value-based pricing in France，Germany，UK，Italy and Sweden were analyzed，so as to provide the suggestions for medical insurance reimbursement of multi-indication drugs in China. RESULTS & CONCLUSIONS：The realization of value-based pricing first needed to develop a value framework to define，measure and integrate value，and then established a model to convert the total value into price. The overall idea of value-based pricing for multi-indication drugs was consistent，but there were differences in the value standard. In the UK and Sweden， quality-adjusted life years （QALYs） and incremental cost-effectiveness ratios （ICERs） measured by pharmacoeconomicsare used as the value standard. France，Germany and Italy were more focused on the therapeutic value and clinical benefit improvement. As for medical insurance reimbursement strategies，France adopted single weighting method based on expected volume. Germany adopted combination weighting method based on value and volume. UK introduced the Patient Access Schemes and Italy introduced the Managed Entry reements，both based on the nominal reimbursement standard. Sweden adopted independent reimbursement for different indications by different brand names. It is suggested that China can explore the value-based pricing strategies of multi-indication drugs on the basis of the above international experiences，reference and use these variety of medical insurance reimbursement strategies comprehensively. Simultaneously，the information collection mechanism of patients and drug use should be improved to provide data support for the implementation of China’s value-based pricing and reimbursement strategies for multi-indication drugs.

Critérios de definição de preços de medicamentos no Brasil e em países selecionados: uma revisão comparada / Criteria for setting drug prices in Brazil and selected countries: a comparative review

Objetivos: Comparar os critérios de formação de preços de medicamentos no Brasil e em países selecionados, analisar o mecanismo de formação de preços de medicamentos no Brasil e analisar o mecanismo de formação de preços de medicamentos em países selecionados. Métodos: Foi realizada uma revisão narrativa da literatura por meio do levantamento de informações em bases de dados, em sites das agências nacionais e organismos internacionais e em literatura "cinzenta", a respeito dos sistemas de saúde e mecanismos de formação de preços de medicamentos no Brasil e nos países selecionados (Austrália, Canadá, Espanha, Estados Unidos, França, Grécia, Itália, Nova Zelândia e Portugal). Resultados: A maioria dos países pesquisados utiliza o referenciamento externo e interno de preços, realiza ajustes e correções de preços ao longo do tempo e faz estudos de avaliação econômica. O valor da terapia ou seu benefício para o paciente ou sistema de saúde é um fator importante tanto na determinação do preço como da incorporação no sistema de saúde. Conclusão: Este trabalho permitiu identificar as semelhanças entre as práticas recomendadas e implementadas internacionalmente e as realizadas no Brasil, bem como os problemas relacionados à definição de preços das novas terapias, além das lacunas no modelo regulatório atual

Objectives: To compare the criteria for setting prices of medicines in Brazil and in selected countries, to analyze the mechanism for setting prices of medicines in Brazil and to analyze the mechanism for setting prices of medicines in selected countries. Methods: A narrative review of the literature was carried out by collecting information in databases, on websites of national agencies and international organizations and in "gray" literature, regarding health systems and price formation mechanisms of medicines in Brazil and selected countries (Australia, Canada, Spain, United States, France, Greece, Italy, New Zealand and Portugal). Results: Most of the countries surveyed use external and internal price referencing, make price adjustments and corrections over time and carry out economic evaluation studies. The value of therapy or its benefit to the patient or health care system is an important factor in both pricing and incorporation into the health care system. Conclusion: This work allowed identify the similarities between the practices recommended and implemented internationally and those carried out in Brazil, as well as the problems related to the pricing of new therapies, in addition to the gaps in the current regulatory model

Attitude and medical insurance coverage for off-label use in various countries / 中华医院管理杂志

Off-label drug use is a global problem in clinical practice. The management status, attitude and medical insurance coverage of off-label drug use are different in various countries. By analyzing the management and reimbursement policy of off-label drug use in other countries, the authors suggested that China should speed up the institutional arrangements of off-label drug use and establish relevant management systems, and strengthen the supervision of off-label drug use, so as to guarantee the rights of patients to the best treatment.

How reimbursements of blood expenses affect the voluntary blood donation recruitment: A comparative study / 中国输血杂志

【Objective】 To discuss the influence of direct reimbursement of blood expenses in hospitals on the recruitment of blood donors in Xianyang City. 【Methods】 Blood donors or reimbursers, who reimbursed blood expenses either at hospitals or at our blood center were investigated, and these two kinds of blood expense reimbursements were compared in terms of convenience, the impact on the enthusiasm of blood donation, as well as the impact of the awareness of hospital reimbursement on the recruitment of blood donors. 【Results】 The direct reimbursement of blood expenses at hospitals took 22 minutes per person, without any round trips nor transportation costs. The rate of satisfaction, long-term intention to blood donation, and voluntary mobilization of others were 98.11%, 91.89%, and 82.56%, respectively, higher than those in the reimbursers at blood station(P<0.01). 35.16%, 38.90%, 98.56%, 94.24% and 93.37% of the blood donors, who were aware of benefits of hospital reimbursement, had donated for 2~3 times, donated more than 3 times, satisfied with the way of reimbursement, intended to redonate and mobilize others, which were higher than those who were unaware of the the hospital reimbursement(P<0.05). 【Conclusion】 Direct reimbursement of blood expenses at hospitals not only improved the convenience, but also increased the enthusiasm of blood donors by improving their satisfaction, which was conductive to blood donation recruitment.

Free blood use among voluntary blood donors in Shiyan city / 中国输血杂志

【Objective】 To analyze the situation of free blood use and direct reimbursement of blood expenses in Shiyan city, so as to provide basis for more effective service of free blood use and direct reimbursement of blood expense after blood donation, and recruitment and retain of blood donors. 【Methods】 The data of free blood use from 1999 to 2019 in Shiyan city were collected for statistical analysis. Measurement data were described by mean±SD, and enumeration data were described by rate or construction ratio. Chi-square test was used for comparison of construction ratio or rate of stratified groups. 【Results】 In the past 21 years, free blood use has developed from the overall increasing stage (1999~2014) to the overall stable stage (2014~2019). Free blood use accounted for 3.52%(40 722.11/1 156 307.85)of the blood donation. Among the blood recipients, blood donors themselves accounted for only 18.83%(2 240/11 898), far lower than the proportion of their direct relatives. Since 2013, Shiyan has carried out the direct reimbursement of clinical blood expenses of voluntary blood donors according to the unified requirements of Hubei Province. The direct reimbursement rate over the past 7 years was 76.49%(5 397/7 056), and the proportion of people from other cities who applied for reimbursement was 4.02%(284/7 056). 【Conclusion】 The policy of free blood use and blood expense direct reimbursement has promoted the development of blood donation. It can also be further improved by relaxing the reimbursement scope of free blood use, strengthening publicity, optimizing services, strengthening supervision, using WeChat public service platform to carry out remote free blood, and strengthening national network construction.

Practice of reimbursement of blood expenses in hospital using information platform / 中国输血杂志

【Objective】 To facilitate the reimbursement of blood expenses in the hospital through information platform and promote the healthy development of blood donation. 【Methods】 The publicity of blood expense reimbursement was conducted through the hospital information platform,, and direct reimbursement of clinical blood use of voluntary blood donors and their relatives was achieved using the hospital reimbursement management system and Ding Talk office platform. 【Results】 Compared with the traditional mode of reimbursement of blood expenses through blood stations after discharge, direct reimbursement in the hospital simplified the reimbursement process, shortened the distance and time, and improved the satisfaction of blood donors and their relatives significantly. 【Conclusion】 As a new reimbursement model, reimbursement of blood expenses directly in the hospital can improve the satisfaction of blood donors and their relatives, and promote the healthy development of blood donation.

Caracterización y análisis de los elementos básicos de los mecanismos de pago en salud y tipologías más frecuentes / Characterization and analysis of the basic elements of health payment mechanisms and their most frequent types

INTRODUCCIÓN: Los sistemas de salud se desarrollan en ámbitos complejos y con fallas constantes (incertidumbre, asimetría de información, problema de relación de agencia e inducción de demanda). Estas fallas determinan las relaciones e incentivos entre los actores y se basan en la imperfección del sector. Frente a ello, los mecanismos de pago regulan aspectos del comportamiento e incentivos del sistema, participando como instrumentos de compra de atenciones de salud a prestadores, mediados por los seguros de salud en representación de los usuarios. OBJETIVO: Caracterizar los elementos básicos de las tipologías más frecuentes de los mecanismos de pago con el propósito de para apoyar la labor de los prestadores en su relación con pagadores. MÉTODOS: Se condujo una revisión dirigida de la evidencia en PubMed, Google, Google Scholar y selección estratégica en bola de nieve. Los mecanismos de pago están conformados por tres variables microeconómicas clásicas fijas o variables: precio, cantidad y gasto; y dimensiones temporales utilizadas para analizar sus atributos y efectos. De la combinación de estas variables surgen distintos mecanismos. RESULTADOS: Entre los más utilizados se describen: pago por servicio, presupuesto global, Bundled Payments, grupos relacionados de diagnóstico, per cápita, pago por desempeño y acuerdos de riesgo compartido. Dentro de sus variables ha cobrado importancia una cuarta, el riesgo financiero. CONCLUSIONES: Los mecanismos de pago resultan esenciales para concatenar esfuerzos sanitarios con la práctica clínica. Permiten regular relaciones entre seguros, prestadores y usuarios. Dependiendo de la arquitectura del mecanismo, estas pueden tornarse beneficiosas o entorpecer el cumplimiento de los objetivos del sistema sanitario.

INTRODUCTION: Healthcare systems are developed in imperfect scenarios, in which there are constant failures (uncertainty, information asymmetry, agency relationship problem, and supply-induced demand). These failures, based on the imperfection of the sector, determine the relationships and incentives between the actors. It is within this context that payment mechanisms regulate aspects of the system behavior and incentives, acting as instruments for the purchasing of health care from providers, mediated by health insurance on behalf of users. OBJECTIVE: To characterize the basic elements of most frequent payment mechanisms to help providers in their relationship with payers. METHODS: A review of the evidence was conducted in PubMed, Google, Google Scholar, and strategic snowball selection. Payment mechanisms consist of three classical microeconomics variables, fixed or variable: price, quantity, and expense. Time dimensions are used to analyze their attributes and effects. Different mechanisms emerge from the combination of these variables. RESULTS: Among the most used are: Fee-For-Service, Global Budget, Bundled Payments, Diagnosis-Related Groups, Per-capita, Performance Pay, and Risk-Sharing Agreements. A fourth has also gained importance: Financial Risk. CONCLUSIONS: Payment mechanisms are essential to link health efforts with clinical practice. They make it possible to regulate relationships between insurers, providers, and users, which, depending on the architecture of the mechanism, can become beneficial or hinder the fulfillment of the objectives of the health system.

Estimating the productivity of radiologists in Brazil: the search for a benchmark / Estimativa da produtividade de radiologistas brasileiros: a busca por um padrão de referência

Abstract Objective: To determine the average productivity of radiologists, as measured by number of reports issued per 6-h shift, evaluating variables that could affect the results. Materials and Methods: This was a study utilizing an online questionnaire sent to radiologists affiliated with the Brazilian College of Radiology and Diagnostic Imaging. The questions were related to the demographic profile and professional practice characteristics (form of remuneration, primary imaging method employed, and subspecialty) of the radiologists, as well as their individual productivity (average personal productivity) and the productivity considered reasonable in a 6-h shift. The association between productivity and the practice characteristics of the radiologists was determined by using Poisson regression to calculate the prevalence ratio. Results: A total of 510 radiologists completed the questionnaire. The great majority of the respondents (84%) reported that their remuneration is directly related to their productivity. The productivity varied according to the subspecialty, work environment, and remuneration model. Conclusion: We demonstrated that the productivity of radiologists is associated with the characteristics of their employment. We hope that this study will encourage other studies aimed at evaluating the productive capacity of the radiologists in Brazil, addressing the various functions they perform in their daily routine, including activities other than issuing reports.

Resumo Objetivo: Estimar a produtividade média dos radiologistas brasileiros em número de laudos emitidos por período de trabalho de seis horas, analisando variáveis que possam influenciar os resultados. Materiais e Métodos: Pesquisa realizada por meio de questionários online respondidos por radiologistas brasileiros afiliados ao Colégio Brasileiro de Radiologia e Diagnóstico por Imagem. As questões incluíram dados demográficos e profissionais dos radiologistas (forma de remuneração, método de imagem de atuação e subespecialidade) e a produtividade individual e a considerada razoável em um período de seis horas de trabalho. A associação entre a produtividade e as características de trabalho dos radiologistas foi calculada pela razão de prevalência, por meio da regressão de Poisson. Resultados: Ao todo, 510 radiologistas responderam ao questionário. A grande maioria dos respondedores (84%) relatou que a sua remuneração está diretamente relacionada à produtividade. A produtividade variou em função da subespecialidade de atuação, ambiente de trabalho e modelo de remuneração. Conclusão: Demonstramos a associação entre a produtividade do radiologista e as características relacionadas à forma de trabalho. Esperamos que este estudo impulsione outras pesquisas que avaliem a capacidade produtiva do radiologista brasileiro, considerando as diversas funções exercidas por este profissional em sua rotina de trabalho, contemplando outras atividades, além da emissão de laudos.

Establishment and Application of Dispensing ，Charging and Reimbursement Mode by Dose of Trastuzumab for Injection / 中国药房

OBJECTIVE：To standardize and optim ize the clinical use of Trastuzumab for injection ，and to provide reference for rational use of drugs in the patients. METHODS ：The pharmacy intravenous admixture service （PIVAS）in our hospital took the lead in communication and coordination with financial ，information，medical insurance departments as well as clinicians and nurses，to set up dispensing ，charging and reimbursement mode by dose of trastuzumab. Under that ，doctors could give orders according to the clinical dosage of patients ；PIVAS dispenses drugs according to the actual dose ；the drugs were shared among patients；the charge and reimbursement of drugs are carried out according to the actual dose of patients. At the same time ，the questionnaire survey was conducted among 60 patients about the medical experience and cost savings before and after the implementation of the mode . RESULTS ：The questionnaire survey showed that in terms of solving the potential safety problems of trastuzumab and the inconvenience of patients ’medical treatment ，the solution rate of the mode was 100％；in terms of improving patients’feeling of seeking medical treatment and helping treatment ，the improvement rate was 100％；in terms of saving patients ’ treatment costs ，most（80％）of the patients thought that it could save less than 500 yuan each time ，and rest of the patients thought that it could save more than 500 yuan each time. CONCLUSIONS ：The mode of dispensing ，charging and reimbursement of Trastuzumab for injection in our hospital has solved the problems of drug waste ，occupational injury and inconvenient preservation in clinical use ，and has played a good role in drug safety ，cost saving and patient convenience.

Discussion on the management mode of real-time reimbursement of testing expense in clinical trials / 中华医学科研管理杂志

Objective:To explore the management mode of the real-time reimbursement of testing expenses in clinical trials, dealing with the possible disadvantages of manual reimbursement and improving work efficiency.Methods:Based on hospital information system, the GCP center integrates the clinical trial information system, optimizes the trial reimbursement process, and explores a unique " clinic-GCP-finance" streamlined clinical trial real-time settlement management model.Results:This management mode of real-time reimbursement of testing expenses has been adopted for 3 years. This management model enables human subjects to complete the reduction or exemption of clinical trial-related medical testing expenses before making the payments, which is also highly praised by both investigators and subjects.It complied with informatization and technology development in the era of big data, realized full process dynamic supervision over clinical trial lab testing expenses and avoided management delay. It also had advantages in simplifying reimbursement process, reducing work load and mistakes, complying with inspection and improving trial quality.Conclusions:Clinical trial real-time reimbursement management mode of testing expenses works better in compliance with GCP, safeguards the rights and interest of human subject, and can provide a certain reference for other GCP centers.